Company Description
Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States.
The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.
It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-related macular degeneration and other retinal diseases; PAXTRAVA, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease.
In addition, the company offers modulator for intermediate and late dry age-related macular degeneration; and gene delivery for inherited retinal degenerations and protein biofactory indications.
The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC.
Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.
| Country | United States |
| Founded | 2006 |
| IPO Date | Jul 25, 2014 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 267 |
| CEO | Dr. Pravin U. Dugel M.D. |
Contact Details
Address: 15 Crosby Drive Bedford, Massachusetts 01730 United States | |
| Phone | 781-357-4000 |
| Website | ocutx.com |
Stock Details
| Ticker Symbol | OCUL |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001393434 |
| CUSIP Number | 67576A100 |
| ISIN Number | US67576A1007 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Antony Mattessich | President, Chief Executive Officer and Director |
| Donald Notman Jr. | Chief Financial Officer |
| Dr. Jeffrey S. Heier M.D. | Chief Scientific Officer |
| Dr. Rabia Gurses Ozden M.D. | Chief Medical Officer |
| Dr. Pravin U. Dugel M.D. | Executive Chairman |
| Dr. Karen-Leigh Edwards M.B.A., Ph.D. | Chief Operations Officer |
| Dr. Peter K. Jarrett Ph.D. | Chief Technology Officer |
| Philip C. Strassburger Esq. | General Counsel |
| William H. Ransone II | Vice President of Global Sales and Marketing |
| Tracy Smith | Vice President of Human Resources |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 19, 2024 | PRE 14A | Other preliminary proxy statements |
| Apr 18, 2024 | 8-K | Current Report |
| Mar 29, 2024 | 8-K | Current Report |
| Mar 25, 2024 | S-3ASR | Automatic shelf registration statement of securities of well-known seasoned issuers |
| Mar 11, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 11, 2024 | 10-K | Annual Report |
| Mar 11, 2024 | 8-K | Current Report |
| Feb 27, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Feb 22, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Feb 22, 2024 | 8-K | Current Report |